COMPARATIVE EFFICACY OF ANTIBODIES TO C-TERMINAL FRAGMENT OF BETA-SUBUNIT INSULIN RECEPTOR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

At the end of study it was established that a 6-month combined therapy (metformin 850 mg twice daily and extremely low doses of antibodies to the C-final fragment of insulin receptor 2 tablets 4 times daily) allowed a maintenance of an adequate glycemic control of glucose levels in patients with type 2 diabetes.

pharmacotherapy of type 2 diabetes, new hypoglycemic agent, extremely low doses of antibodies to the C-final fragment of ß-subunit insulin receptor, comparative efficacy of hypoglycemic agents